Source: International Congress 2019 – Biology and prognosis of lung cancer
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
M. Drösslerová (Prague, Czech Republic), M. Sterclová (Prague, Czech Republic), A. Tašková (Prague, Czech Republic), V. Hytych (Prague, Czech Republic), P. Horaždovský (Prague, Czech Republic), E. Richterová (Prague, Czech Republic), M. Smetáková (Prague, Czech Republic), M. Vašáková (Prague, Czech Republic). Role of chemokines in resectable non-small cell lung cancer (NSCLC). 3042

Member's Comments

No comment yet.

Related content which might interest you: 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Radio(chemo)therapy in locally advanced nonsmall cell lung cancer Source: Eur Respir Rev 2015; 25: 65-70 Year: 2016 Prognostic factors for unresectable non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 270s Year: 2002 Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro Year: 2020 Radiotherapy for stage III non-small cell lung cancer (NSCLC) Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 How to treat a T1-T3N0 non-small cell lung cancer (NSCLC) with isolated brain metastasis Source: International Congress 2015 – How to treat brain metastases Year: 2015 Lung cancer Source: Respipedia Article Year: 2018 Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Changes of lung function in patients with non-small cell lung cancer tretaed by chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 771s Year: 2006 Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo). Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015 Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Treatment of  non-small cell lung cancer (NSCLC) - the state of the art and beyond Source: International Congress 2017 – State of the art session: "Lung cancer" Year: 2017 XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006 Combined radiotherapy for nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003 Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Anticancer treatment for advanced non-small cell lung cancer Source: Breathe 2011; 8: 124-133 Year: 2011